首页|Dawn of CAR-T cell therapy in autoimmune diseases

Dawn of CAR-T cell therapy in autoimmune diseases

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
Chimeric antigen receptor(CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies.Based on the immunomodulatory capability of CAR-T cells,efforts have turned toward exploring their potential in treating auto-immune diseases.Bibliometric analysis of 210 records from 128 academic journals published by 372 institutions in 40 countries/regions indicates a growing number of publications on CAR-T therapy for autoimmune diseases,covering a range of subtypes such as systemic lupus erythematosus,multiple sclerosis,among others.CAR-T therapy holds promise in mitigating several shortcomings,including the indiscriminate suppression of the immune system by traditional immunosuppressants,and non-sus-taining therapeutic levels of monoclonal antibodies due to inherent pharmacokinetic constraints.By persisting and proliferating in vivo,CAR-T cells can offer a tailored and precise therapeutics.This paper reviewed preclinical experiments and clinical trials involving CAR-T and CAR-related therapies in various autoimmune diseases,incorporating innovations well-studied in the field of hematological tumors,aiming to explore a safe and effective therapeutic option for relapsed/refractory autoimmune diseases.

CAR-T cell therapyAutoimmune diseaseImmunotherapyMultiple sclerosisNeuromyelitis optica spectrum disorderSystemic lupus erythematosus

Yuxin Liu、Minghao Dong、Yunhui Chu、Luoqi Zhou、Yunfan You、Xiaowei Pang、Sheng Yang、Luyang Zhang、Lian Chen、Lifang Zhu、Jun Xiao、Wei Wang、Chuan Qin、Daishi Tian

展开 >

Department of Neurology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430030,China

Hubei Key Laboratory of Neural Injury and Functional Reconstruction,Huazhong University of Science and Technology,Wuhan,Hubei 430030,China

Ministry of Science and Technology China Brain Initiative Grant STI2030-Major Projects国家自然科学基金国家自然科学基金国家自然科学基金国家自然科学基金Knowledge Innovation Program of Wuhan Shuguang Project

2022ZD0204700823714048227134182071380818737432022020801020454

2024

10.1097/CM9.0000000000003111

中华医学杂志(英文版)
中华医学会

中华医学杂志(英文版)

CSTPCD
影响因子：0.838
ISSN：0366-6999
年,卷(期)：2024.137(10)
  • 90